EPIVIN: For Investigators

Phase II clinical trial investigating the use of epigallocatechin-3-gallate (Veregen) in the treatment of vulval intraepithelial neoplasia.




Change of Staff

If there is a change of staff working on the trial please print off and complete the relevant registration form below. Please also ensure that the Signature and Delegation Log is updated. Return both documents to the EPIVIN Trial Office.

Trial Documents

Links to the current protocol, Patient Information Sheet, Informed Consent Form are provided below. If there has been a recent amendment to the trial please ensure you have R&D approval before using these documents.

Other documents (e.g. Amendments, Case Report Form, Serious Adverse Event Form, Guidelines, GP Letter, Release of Medical Information Form etc) can be found by clicking on the other menu items below. If you cannot find what you are looking for please contact the EPIVIN Trial Office.

Version Control Lists

The version numbers and dates of all documents used for the trial are captured on a Version Control List. Links to the Version Control Lists used in this trial are below in reverse date order.


Below is a link to a document which lists all of the substantial protocol amendments which have been made for this trial. The folders below contain the relevant amended documentation and approval letters. Please ensure that you have R&D approval (if applicable) before using the latest versions of these documents.

Case Report Form


Other Trial Documents

Contact Details

Chief Investigator
Professor David Luesley
Contact via the SWBH switchboard on 0121 554 3801

EPIVIN Trial Office
Trial Coordinator:                                            Baljit Kaur
Trial Monitor:                                                   Poonam Patel
Trial Management Team Leader:                 Sarah Bowden
Trial Statistician:                                              Daniel Slade

Cancer Research UK Clinical Trials Unit (CRCTU)
University of Birmingham
B15 2TT

Tel:      (+44) 0 121 414 5102
Fax:      (+44) 0 121 414 2230
Email:  EPIVIN@trials.bham.ac.uk

Trial Entry
Tel: 0800 371 969    (9.00 am till 5.00 pm Monday to Friday)

Serious Adverse Event Reporting
Fax: 0121 414 2230  or  0121 414 3700

The University of Birmingham,
B15 2TT

Sandwell & West Birmingham Hospitals NHS Trust
Dudley Road
B18 7QH